Forecast

The analysts' average price target is €99.76 (-21.00%). The median is €105.62 (-16.36%).

Buy	8
Hold	16
Sell	5

News Go to news feed

Moderna recovers from selling pressure thanks to cancer vaccine pipeline and approvals

Moderna shares rose about 7.5% in the morning to $146.84, recovering markedly from sell‑offs that had pushed the stock below its 52‑week high. Drivers include a reassessment of the previously negative view from Rothschild & Co Redburn, the Phase‑3 success of the personalized cancer vaccine Intismeran Autogen (together with Merck), and recent US approvals for updated COVID‑19 vaccines and the flu vaccine mFLUSIVA. Additional tailwinds come from a raise by Argus (price target $180), the upcoming presentation at the Morgan Stanley Global Healthcare Conference, and a positive market environment. » More on de.investing.com
Moderna: analysts dampen euphoria after rally around personalized cancer vaccine

After positive results with a personalized cancer vaccine, Moderna shares jumped, but Berenberg keeps a "Hold" rating and raises the price target to $100 while still seeing about 25% downside. The bank models a 95% chance of approval in melanoma and at most $3.5 billion in sales, but warns of missing detailed efficacy data and immature overall survival. Transferability of the effects to other cancer types is uncertain, and the recent rally was also boosted by short-covering; Moderna now needs to provide further details. » More on deraktionaer.de
Moderna shares: about 70% loss five years after purchase

Five years ago the Moderna share was trading at $449.38; on Sept. 9, 2026 it closed at $135.61. A $1,000 investment at that time would therefore have fallen to about $301.77, a loss of 69.82%. The market value of all Moderna shares was most recently around $55.90 billion; stock splits and dividends were not taken into account in the calculation. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Moderna Inc. has already paid €0.17 in dividends. The last payout was in May 2022.

Financials

In the last quarter, Moderna Inc. had revenue of €127.05m and net profit of -€685.2m

(EUR)	June 2026	YoY
Revenue	127.05m	5.46%
Gross profit	45.56m	133.49%
Net profit	-685.2m	2.11%
EBITDA	-616.85m	4.33%

Fundamentals

Metric	Value
Market capitalization	€46.39bn
Number of shares	396.79m
52-week high/low	€152.31 - €19.21
Dividends	No
Beta	0.90
P/E ratio	-16.99
PEG ratio	2.01
P/B ratio	7.94
P/S ratio	24.15

Company profile

Moderna, Inc., ein Biotechnologieunternehmen, entdeckt, entwickelt und vermarktet Boten-RNA-Therapeutika und Impfstoffe zur Behandlung von Infektionskrankheiten, Immunonkologie, seltenen Krankheiten, Herz-Kreislauf-Erkrankungen und Autoimmunerkrankungen in den Vereinigten Staaten, Europa und international. Die Impfstoffe gegen Atemwegserkrankungen umfassen COVID-19, Grippe, Respiratory Syncytial Virus, Endemic HCoV und hMPV+PIV3; die latenten Impfstoffe umfassen Cytomegalovirus, Epstein-Barr-Virus, Humanes Immundefizienz-Virus, Herpes-Simplex-Virus und Varizella-Zoster-Virus; und die Impfstoffe für die öffentliche Gesundheit bestehen aus Zika- und Nipah-Impfstoffen. Das Unternehmen bietet auch systemische sekretorische und Zelloberflächentherapeutika, Krebsimpfstoffe wie personalisierte Krebs-, KRAS- und Checkpoint-Impfstoffe, intratumorale Immuno-Onkologieprodukte, lokalisierte regenerative, systemische intrazelluläre und inhalative pulmonale Therapeutika an. Das Unternehmen unterhält strategische Allianzen mit AstraZeneca PLC, Merck & Co, Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc; Metagenomi, Inc; der Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; und der Bill & Melinda Gates Foundation sowie eine Kooperations- und Lizenzvereinbarung mit Chiesi Farmaceutici S.P.A. Das Unternehmen war früher als Moderna Therapeutics, Inc. bekannt und änderte im August 2018 seinen Namen in Moderna, Inc. Moderna, Inc. wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.

Name	Moderna Inc.
CEO	Stéphane Bancel
Headquarters	Cambridge, ma USA
Website	investors.modernatx.com/overview/default.aspx
Sector	Health Care
Industry	Biotechnology
IPO	07/12/2018
Employees	4,700